Medicine, Rheumatology Division

Grants

Grants per year 1993 2002 2003 2005 2007 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2019 2020 2031

• 58 Active
• 489 Finished

Grants per year

Search results

• Prot #SBT777101-01: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

  Ruderman, E. M. (PD/PI) & Ruderman, E. M. (PD/PI)

  Medpace Clinical Research LLC, Sonoma Biotherapeutics, Inc.

  4/14/23 → 12/12/26

  Project: Research project

• Prot# SL0010: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of The Efficacy and Safety of four 12-week Treatment Cycles (48 weeks total) Of Epratuzumab in Systematic Lupus Erythematosus Subjects With Moderate To Severe Disease

  Hsieh, C. (PD/PI)

  Parexel, UCB Biosciences, Inc.

  12/13/11 → 12/13/14

  Project: Research project

• Prot#SL0012: A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability Of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4)

  Hsieh, C. (PD/PI)

  Parexel, UCB Biosciences, Inc.

  5/18/12 → 5/18/15

  Project: Research project

• Prot# SL105: The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study

  Ramsey-Goldman, R. (PD/PI)

  XDx Inc.

  7/1/08 → 7/31/10

  Project: Research project

• Prot# SL105: The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study

  Ramsey-Goldman, R. (PD/PI)

  XDx Inc.

  7/1/08 → 7/31/10

  Project: Research project

• Prot #SPM-020: Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study

  Ruderman, E. M. (PD/PI)

  SetPoint Medical Corp

  12/9/22 → 12/9/25

  Project: Research project

• Prot# U2971g: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe Systemic Lupus Erythematosus

  Ramsey-Goldman, R. (PD/PI)

  PPD Development, Genentech, Inc

  1/20/06 → 10/6/10

  Project: Research project

• Prot# WA17043/U2644g: A Randomized, Multifactorial, Double-Blind, Parallel-Group, Dose-Ranging Study of the Efficacy and Safety of Rituximab (Mabthera®/Rituxan®) In Combination with Methotrexate in Patients with Active Rheumatoid Arthritis

  Ruderman, E. M. (Co-PD/PI)

  Genentech, Inc

  7/11/03 → 6/1/07

  Project: Research project

• Prot# WA17043/U2644g: A Randomized, Multifactorial, Double-Blind, Parallel-Group, Dose-Ranging Study of the Efficacy and Safety of Rituximab (Mabthera®/Rituxan®) In Combination with Methotrexate in Patients with Active Rheumatoid Arthritis

  Ruderman, E. M. (Co-PD/PI)

  Genentech, Inc

  7/11/03 → 6/1/07

  Project: Research project

• Prot# WA18062: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Reduction of Signs and Symptoms During Treatment with MRA vs. Placebo, in Combination with Methotrexate in Patients with Moderate to Sever

  Ruderman, E. M. (PD/PI)

  Hoffman-La Roche, Inc.

  9/23/05 → 9/11/10

  Project: Research project

• Prot# WA18063B: A Rndmzd, Dbl-Blnd, Plcb-Cntrlld, Prllel Grp Stdy of the Sfty & Rdctn of Sgn & Symptms Drng Trtmnt w/ MRA vs Plcb, In Cmbntn w/ Trdtnl DMARD Thrpy in Ptnts w/ Mdrt to Svre Actv Rhumtd Arthrts & an indqt rspns to crrnt DMARD Thrpy

  Ruderman, E. M. (PD/PI) & Schnitzer, T. J. (Co-PD/PI)

  Hoffman-La Roche, Inc.

  7/11/05 → 9/10/10

  Project: Research project

• Prot# WA18696B: Long-Term Extenstion Study of Safety During Treatment with Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies

  Ruderman, E. M. (PD/PI)

  Hoffman-La Roche, Inc.

  7/3/07 → 10/3/07

  Project: Research project

• Prot# WA18696B: Long-Term Extenstion Study of Safety During Treatment with Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies

  Ruderman, E. M. (PD/PI)

  Hoffman-La Roche, Inc.

  7/3/07 → 10/3/07

  Project: Research project

• Prot# WA20495 / ACT3986g: A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis who have an Inadequate Response to at Least One A

  Ruderman, E. M. (PD/PI)

  Quintiles, Inc., Genentech, Inc

  8/10/07 → 8/10/10

  Project: Research project

• Prot# WA20495 / ACT3986g: A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis who have an Inadequate Response to at Least One A

  Ruderman, E. M. (PD/PI)

  Quintiles, Inc., Genentech, Inc

  8/10/07 → 8/10/10

  Project: Research project

• Prot# WA20499 / ACT4071g: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus

  Ramsey-Goldman, R. (PD/PI)

  Quintiles, Inc., Genentech, Inc

  1/11/08 → 1/11/11

  Project: Research project

• Prot #WI223665: A Novel Treatment Approach for Rheumatoid Arthritis

  Stehlik, C. (PD/PI)

  Pfizer Inc.

  4/8/17 → 3/15/19

  Project: Research project

• Prot #WI227114: Role of transcriptional profiles in synovial tissue macrophages in the onset of rheumatoid arthritis

  Pope, R. M. (PD/PI), Mandelin, A. M. (Co-Investigator), Perlman, H. R. (Co-Investigator) & Winter, D. R. (Co-Investigator)

  Pfizer Inc.

  9/7/17 → 9/7/20

  Project: Research project

• Prot# WX17801: A Prospective, Rndmzd, Dbl-Blind, Active Cntrlld, Parallel Group, Multi-Center Trial to Assess the Efficacy & Safety of Mycophenolate Mofetil (MMF) in Inducing Response & Maintaining Remission in Sbjts w/Lupus Nephritis {ALMS}

  Ghossein, C. (PD/PI) & Ramsey-Goldman, R. (Co-PD/PI)

  PPD Development, Aspreva Pharmaceuticals Corporation

  10/28/05 → 10/26/10

  Project: Research project

• Prot #XmAb5871-04: A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity

  Ramsey-Goldman, R. (PD/PI)

  PPD Investigator Services, LLC, Xencor, Inc.

  9/13/16 → 9/13/19

  Project: Research project

• PYRIN Proteins as Regulators of Innate Immune Pathways

  Stehlik, C. (PD/PI), Dorfleutner, A. (Co-PD/PI), Perlman, H. R. (Co-PD/PI) & Dorfleutner, A. (Co-Investigator)

  National Institute of General Medical Sciences

  9/4/07 → 3/31/13

  Project: Research project

• PYRIN Proteins as Regulators of Innate Immune Pathways

  Stehlik, C. (PD/PI) & Perlman, H. R. (Co-PD/PI)

  National Institute of General Medical Sciences

  9/30/09 → 8/31/12

  Project: Research project

• Ramsey-Goldman LFA IMPACT 2023-2024

  Ramsey-Goldman, R. (PD/PI) & Ramsey-Goldman, R. (PD/PI)

  Lupus Foundation of America, Inc., Office of the Assistant Secretary for Health

  9/30/23 → 9/29/25

  Project: Research project

• Ravi, Patel

  Pope, R. M. (PD/PI), Sharma, L. (PD/PI), Sharma, L. (PD/PI), Sharma, L. (PD/PI) & Pope, R. M. (Co-Investigator)

  National Center for Advancing Translational Sciences

  7/15/19 → 6/30/25

  Project: Research project

  • Grant Funding 100%
  • Career Development 100%
  • Authors 66%
  • NIH Funding 50%
  • Sustained Impact 50%

• REF Rheumatology Fellowship Training Award

  Pope, R. M. (PD/PI)

  Rheumatology Research Foundation

  7/1/08 → 6/30/09

  Project: Research project